{"id":65875,"date":"2026-05-21T14:20:36","date_gmt":"2026-05-21T06:20:36","guid":{"rendered":"https:\/\/flcube.com\/?p=65875"},"modified":"2026-05-21T14:20:37","modified_gmt":"2026-05-21T06:20:37","slug":"transcenta-and-inhibrx-report-20-response-rate-for-ozekibart-in-heavily-pretreated-colorectal-cancer-following-recent-fda-filing-for-chondrosarcoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65875","title":{"rendered":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Transcenta Holdings Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6628:HKG\">HKG: 6628<\/a>) and its U.S. partner <strong>Inhibrx Biosciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/INBX:NASDAQ\">NASDAQ: INBX<\/a>) announced positive interim results from a Phase I\/II study of <strong>ozekibart (INBRX-109)<\/strong> in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a <strong>20% objective response rate (ORR)<\/strong> in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsors<\/strong><\/td><td>Transcenta Holdings Ltd (HKG: 6628) &amp; Inhibrx Biosciences, Inc. (NASDAQ: INBX)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Ozekibart (INBRX-109)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Tetravalent DR5 agonist antibody inducing tumor-selective cell death<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase I\/II, ozekibart + FOLFIRI combination<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Heavily pretreated locally advanced\/metastatic unresectable CRC<\/td><\/tr><tr><td><strong>Evaluable Patients<\/strong><\/td><td>45<\/td><\/tr><tr><td><strong>Concurrent Development<\/strong><\/td><td>FDA market filing submitted last month for chondrosarcoma indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-efficacy-results\" class=\"wp-block-heading\">Key Efficacy Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Ozekibart + FOLFIRI<\/th><th>Historical Standard-of-Care<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td>20%<\/td><td>1-6%<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (mPFS)<\/strong><\/td><td>5.5 months<\/td><td>~3-4 months<\/td><\/tr><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td>87%<\/td><td>~50-60%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-regulatory-status-amp-development-strategy\" class=\"wp-block-heading\">Regulatory Status &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chondrosarcoma:<\/strong> Fast Track and Orphan Drug designations granted by U.S. FDA; market filing submitted April 2026<\/li>\n\n\n\n<li><strong>Colorectal Cancer:<\/strong> Phase I\/II interim data supports potential pivotal trial advancement<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> Transcenta holds development and commercialization rights for mainland China, Hong Kong SAR, Macau SAR, and Taiwan region<\/li>\n\n\n\n<li><strong>Mechanism Innovation:<\/strong> First-in-class tetravalent DR5 agonist designed to maximize tumor-selective apoptosis while minimizing systemic toxicity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-implications\" class=\"wp-block-heading\">Strategic Market Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The compelling efficacy data in a treatment-refractory CRC population addresses a significant unmet medical need, with current standard regimens showing minimal activity in heavily pretreated patients. The dual-indication strategy\u2014pursuing both the rare chondrosarcoma indication and the broader CRC market\u2014provides multiple pathways to commercial success.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts note that DR5-targeted therapies have historically faced challenges with toxicity and limited efficacy, but ozekibart&#8217;s tetravalent engineering appears to overcome these limitations through enhanced tumor selectivity and potency.<\/p>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-competitive-positioning\" class=\"wp-block-heading\">Commercial Outlook &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity:<\/strong> Addresses $8+ billion global metastatic CRC market with novel mechanism of action<\/li>\n\n\n\n<li><strong>Regulatory Momentum:<\/strong> Chondrosarcoma filing could lead to first approval in 2027, followed by potential CRC indication<\/li>\n\n\n\n<li><strong>Partnership Synergy:<\/strong> Combines Inhibrx&#8217;s U.S. development expertise with Transcenta&#8217;s Greater China commercial infrastructure<\/li>\n\n\n\n<li><strong>Investment Attraction:<\/strong> Strong clinical data likely to enhance partnership and financing opportunities<\/li>\n\n\n\n<li><strong>Therapeutic Differentiation:<\/strong> Novel DR5 mechanism offers alternative to existing targeted therapies and immunotherapies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory submissions, and commercial prospects. Actual results may differ due to regulatory decisions, clinical trial outcomes, and competitive dynamics in oncology therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,975,4421,1616,181],"class_list":["post-65875","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-6628","tag-inhibrx-biosciences","tag-nasdaq-inbx","tag-transcenta"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65875\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma\" \/>\n<meta property=\"og:description\" content=\"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65875\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T06:20:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T06:20:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma\",\"datePublished\":\"2026-05-21T06:20:36+00:00\",\"dateModified\":\"2026-05-21T06:20:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875\"},\"wordCount\":427,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 6628\",\"Inhibrx Biosciences\",\"NASDAQ: INBX\",\"Transcenta\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65875#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65875\",\"name\":\"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-21T06:20:36+00:00\",\"dateModified\":\"2026-05-21T06:20:37+00:00\",\"description\":\"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\\\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65875\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65875#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma - Insight, China&#039;s Pharmaceutical Industry","description":"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65875","og_locale":"en_US","og_type":"article","og_title":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma","og_description":"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.","og_url":"https:\/\/flcube.com\/?p=65875","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-21T06:20:36+00:00","article_modified_time":"2026-05-21T06:20:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65875#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65875"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma","datePublished":"2026-05-21T06:20:36+00:00","dateModified":"2026-05-21T06:20:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65875"},"wordCount":427,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 6628","Inhibrx Biosciences","NASDAQ: INBX","Transcenta"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65875#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65875","url":"https:\/\/flcube.com\/?p=65875","name":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-21T06:20:36+00:00","dateModified":"2026-05-21T06:20:37+00:00","description":"Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I\/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65875#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65875"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65875#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65875"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65875\/revisions"}],"predecessor-version":[{"id":65877,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65875\/revisions\/65877"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}